Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286989 | 0.78 | KDM5A (0.42) | EPHX2 | |
| SCHEMBL298420 | 0.69 | APLNR (0.37) | KCNJ6KCNJ3KCNJ5ALDH1A1KMT2A | |
| SCHEMBL661119 | 0.66 | FAAH (0.42) | — | |
| SCHEMBL661116 | 0.65 | POLB (0.38) | CNR1CNR2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL287304 | 0.62 | HCAR2 (0.43) | ALDH1A1 | |
| SCHEMBL13307838 | 0.61 | CNR1 (0.61) | CNR1EPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL298161 | 0.60 | BRS3 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL5051924 | 0.60 | EPHX2 (1.00) | EPHX2EPHX1MEN1ALDH1A1KMT2A | |
| SCHEMBL3397254 | 0.60 | EPHX2 (1.00) | EPHX2EPHX1MEN1ALDH1A1KMT2A | |
| SCHEMBL6865166 | 0.58 | SIGMAR1 (0.67) | EPHX2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | claimed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | CNR1 968/4885CNR2 994/4885EPHX2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.